Patents by Inventor Isin Dalkilic-Liddle

Isin Dalkilic-Liddle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-transferrin receptor antibodies and uses thereof
    Patent number: 11827702
    Abstract: The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: November 28, 2023
    Assignee: Biogen MA Inc.
    Inventors: Isin Dalkilic-Liddle, Benjamin A. Smith, Karl J. M. Hanf, Fang Qian, R. Blake Pepinsky, Thomas O. Cameron
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
    Publication number: 20230131379
    Abstract: The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
    Type: Application
    Filed: August 31, 2022
    Publication date: April 27, 2023
    Inventors: Isin Dalkilic-Liddle, Benjamin A. Smith, Karl J. M. Hanf, Fang Qian, R. Blake Pepinsky, Thomas O. Cameron
  • HUMAN-DERIVED ANTI-(POLY-GA) DIPEPTIDE REPEAT (DPR) ANTIBODY
    Publication number: 20220153874
    Abstract: Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.
    Type: Application
    Filed: April 25, 2019
    Publication date: May 19, 2022
    Inventors: Jan Grimm, Fabio Montrasio, Isin Dalkilic-Liddle, Mia Marie Rushe, Joseph Walter Arndt